For people with AML, MDS, and CCA

Access and support options

Actor portrayal.

Savings and support

Could the TIBSOVO® (ivosidenib tablets) Copay Program help lower your copay?

If your insurance is commercial (a health insurance plan you have through an employer or through a private plan) and you are eligible, you may pay as little as $0 per prescription for TIBSOVO through the Copay Program.

Who is eligible?*

  • Patients who reside in the U.S., U.S. territories, or Puerto Rico
  • Patients who have a plan through an employer or have a private plan and are paying a portion of the cost

*Not valid for patients whose prescription claims are reimbursed in whole or in part by any state or federal government program, including Medicaid, Medicare, Medigap, Department of Defense (DOD), Veterans Affairs (VA), TRICARE.


TIBSOVO offers additional programs to help patients access their medication depending on their situation

Are insurance delays keeping you from starting treatment?

Learn about the QuickStart Program

Waiting on insurance? The TIBSOVO® QuickStart Program can help during a delay

If your insurance company takes more than 5 business days to approve your treatment, our QuickStart Program is here to help. If you're eligible, we will send you a 30-day supply of your medicine so you do not have to wait to start treatment.*

*As prescribed by your healthcare provider.

Who is eligible?
  • Patients who reside in the U.S., U.S. territories, or Puerto Rico
  • Patients who are government insured, have a plan through an employer, or have a private plan
How to enroll

Fill out the appropriate sections of the TIBSOVO Enrollment Form and then work with your healthcare provider to complete it. Your healthcare provider will fax your completed form to ServierONE Patient Support Program at 1-877-770-7102.

Need help accessing your medication during a temporary coverage gap?

Learn about the Bridge Program

The Bridge Program helps you get treatment during a short-term insurance coverage gap

Changing insurance? Waiting on new insurance? The Bridge Program is designed to provide a one-time, 1‑month supply of TIBSOVO to a qualified patient experiencing a short‑term lapse in coverage.

This program gives you access to TIBSOVO while your insurance issues are being resolved.

Who is eligible?*
  • Patients who reside in the U.S., U.S. territories, or Puerto Rico
  • Patients who have a plan through an employer or have a private plan

*Not valid for patients whose prescription claims are reimbursed in whole or in part by any state or federal government program, including Medicaid, Medicare, Medigap, Department of Defense (DOD), Veterans Affairs (VA), TRICARE.

How to enroll

Fill out the appropriate sections of the TIBSOVO Enrollment Form and then work with your healthcare provider to complete it. Your healthcare provider will fax your completed form to ServierONE Patient Support Program at 1-877-770-7102.


ServierONE patient support

Find additional support and guidance to help you pay for TIBSOVO

Personalized support

Dedicated Patient Experience Managers can help you navigate insurance, financial support, and access to your treatment.

Government insurance support

Financial assistance resources for people with Medicare, Medicaid, TRICARE, VA, DOD, and other government healthcare programs are available.

Uninsured & underinsured support

People who are uninsured or experience gaps in coverage may be eligible for programs that help with access to treatment.

Email USPatientServices@servier.com or call 1‑800‑813‑5905 (Monday-Friday, 8 AM to 8 PM ET) to contact a Patient Services representative directly.

Please see ServierONE.com for full Terms and Conditions for each program.

Downloadable resources

TIBSOVO resources that can help

The downloadable materials below may be helpful to you and your healthcare team.

TIBSOVO® (ivosidenib tablets) Medication Guide.

Medication Guide

Important information to know about taking TIBSOVO.

TIBSOVO® (ivosidenib tablets) AML Patient Brochure.

TIBSOVO AML Patient Brochure

Your guide to IDH1-targeted AML treatment with TIBSOVO.

TIBSOVO® (ivosidenib tablets) MDS Patient Brochure.

TIBSOVO MDS Patient Brochure

Your guide to IDH1-targeted MDS treatment with TIBSOVO.

TIBSOVO® (ivosidenib tablets) CCA Patient Brochure.

TIBSOVO CCA Patient Brochure

Your guide to IDH1-targeted CCA treatment with TIBSOVO.

TIBSOVO® (ivosidenib tablets) Dosing Calendar.

TIBSOVO Dosing Calendar

Use this TIBSOVO dosing calendar to ensure you are taking every dose.

Differentiation Syndrome Reference Card.

Differentiation Syndrome Reference Card

This card will let your healthcare provider(s) know that you are taking a medication that can cause differentiation syndrome. Fill it out and keep it with you at all times. Be sure to show it to any person involved in your medical care.



Patient advocacy

Patient advocacy, support, and assistancea

AA.MDS International Foundation (AAMDSIF)

1-800-747-2820

aamds.org

American Cancer Society®

1-800-227-2345

cancer.org/cancer/leukemia

Cancer Support Community

1-888-793-9355

cancersupportcommunity.org

Cholangiocarcinoma Foundation

1-801-999-0455

cholangiocarcinoma.org/

HealthTree Foundation

1-800-709-1113

healthtree.org

HealthWell Foundation®

1-800-675-8416

healthwellfoundation.org

Patient Advocate Foundation

1-800-532-5274

patientadvocate.org

aThese are independent resources. Financial support eligibility is determined by the individual foundation. Servier Pharmaceuticals is not affiliated with these organizations.

 

What is TIBSOVO?

TIBSOVO is a prescription medicine used to treat adults with an isocitrate dehydrogenase-1 (IDH1) mutation with:

  • acute myeloid leukemia (AML):
    • with newly diagnosed AML treated in combination with azacitidine or alone who are 75 years or older or who have health problems that prevent the use of certain chemotherapy treatments
    • when the disease has come back or has not improved after previous treatment(s)
  • myelodysplastic syndromes (MDS):
    • when the disease has come back or has not improved after previous treatment(s)
  • bile duct cancer (cholangiocarcinoma):
    • with bile duct cancer that has spread and
    • who have already received previous treatment(s)

Your healthcare provider will perform a test to make sure that TIBSOVO is right for you. It is not known if TIBSOVO is safe and effective in children.

 

IMPORTANT SAFETY INFORMATION

TIBSOVO may cause serious side effects, including:

  • Differentiation syndrome. Differentiation syndrome is a common condition that affects your blood cells and may be life-threatening or lead to death. Differentiation syndrome in adults with AML and MDS has happened as early as 1 day and up to 3 months after starting TIBSOVO. Call your healthcare provider or go to the nearest hospital emergency room right away if you develop any of the following symptoms of differentiation syndrome during treatment with TIBSOVO:
  • fever
  • cough
  • trouble breathing
  • rash
  • decreased urination
  • dizziness or lightheadedness
  • rapid weight gain
  • swelling of your arms and legs

If you develop signs and symptoms of differentiation syndrome, your healthcare provider may treat you with a corticosteroid medicine or a medicine called hydroxyurea and may monitor you in the hospital.

  • Changes in the electrical activity of your heart called QTc prolongation. QTc prolongation can cause irregular heartbeats that can be life-threatening. Your healthcare provider will check the electrical activity of your heart with a test called an electrocardiogram (ECG) before and during treatment with TIBSOVO. Tell your healthcare provider right away if you feel dizzy, lightheaded, or faint
  • Guillain-Barré syndrome has happened in people treated with TIBSOVO. Your healthcare provider will monitor you for nervous system problems and will permanently stop your treatment with TIBSOVO if you develop Guillain-Barré syndrome. Tell your healthcare provider right away if you develop any signs or symptoms of Guillain-Barré syndrome, including:
  • weakness or tingling feeling in your legs, arms, or upper body
  • numbness and pain on one side or both sides of your body
  • any changes in your ability to see, touch, hear, or taste
  • burning or prickling sensation
  • difficulty breathing

The most common side effects of TIBSOVO when used in combination with azacitidine or alone in adults with AML include:

  • changes in certain blood cell counts
  • diarrhea
  • increased blood sugar
  • fatigue
  • changes in certain liver function tests
  • swelling of arms or legs
  • decreased levels of electrolytes in the blood
  • nausea
  • vomiting
  • decreased appetite
  • joint pain
  • shortness of breath
  • uric acid increased
  • stomach (abdominal) pain
  • changes in certain kidney function tests
  • pain or sores in your mouth or throat
  • rash
  • irregular heart rhythm or heartbeat (QTc prolongation)
  • differentiation syndrome
  • muscle pain

The most common side effects of TIBSOVO when used in adults with MDS include:

  • changes in certain kidney function tests
  • changes in certain blood cell counts
  • joint pain, back pain, or neck pain
  • decreased levels of albumin in the blood
  • changes in liver function tests
  • fatigue
  • diarrhea
  • cough
  • decreased levels of sodium in the blood
  • pain or sores in your mouth or throat
  • decreased appetite
  • muscle pain
  • decreased levels of phosphorus in the blood
  • itchy skin
  • rash

The most common side effects of TIBSOVO in adults with cholangiocarcinoma include:

  • fatigue
  • nausea
  • abdominal pain
  • diarrhea
  • cough
  • decreased appetite
  • fluid and swelling in your stomach area
  • vomiting
  • hemoglobin decreased (anemia)
  • rash
  • changes in liver function tests

Your healthcare provider will do blood tests before you start and during treatment with TIBSOVO. Your healthcare provider may decrease, temporarily hold, or permanently stop your treatment with TIBSOVO if you develop certain side effects.

TIBSOVO may cause fertility problems in females and males, which may affect your ability to have children. Talk to your healthcare provider if you have concerns about fertility.

These are not all of the possible side effects of TIBSOVO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Before taking TIBSOVO, tell your healthcare provider about all of your medical conditions, including if you:

  • have any heart problems, including a condition called long QT syndrome
  • have problems with abnormal electrolytes, such as sodium, potassium, calcium, or magnesium levels
  • have nervous system problems
  • have problems with your kidneys or are on dialysis
  • have any liver disorders, including cirrhosis
  • are pregnant or plan to become pregnant. TIBSOVO may cause harm to your unborn baby. You should avoid becoming pregnant during treatment with TIBSOVO. Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with TIBSOVO
  • are breastfeeding or plan to breastfeed. It is not known if TIBSOVO passes into your breast milk. Do not breastfeed during your treatment with TIBSOVO and for 1 month after your last dose of TIBSOVO

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Especially tell your healthcare provider if you take hormonal contraceptives. TIBSOVO may affect how hormonal contraceptives work and may cause them to not work as well.

Please see Full Prescribing Information, including Boxed WARNING for AML and MDS patients and Medication Guide.

Last update: September 2026

Information on this website is reviewed through established medical, legal, and regulatory processes to support accurate, balanced, and label-consistent communication about TIBSOVO.

 

What is TIBSOVO?

TIBSOVO is a prescription medicine used to treat adults with an isocitrate dehydrogenase-1 (IDH1) mutation with:

  • acute myeloid leukemia (AML):
    • with newly diagnosed AML treated in combination with azacitidine or alone who are 75 years or older or who have health problems that prevent the use of certain chemotherapy treatments
    • when the disease has come back or has not improved after previous treatment(s)
  • myelodysplastic syndromes (MDS):
    • when the disease has come back or has not improved after previous treatment(s)
  • bile duct cancer (cholangiocarcinoma):
    • with bile duct cancer that has spread and
    • who have already received previous treatment(s)

Your healthcare provider will perform a test to make sure that TIBSOVO is right for you. It is not known if TIBSOVO is safe and effective in children.

IMPORTANT SAFETY INFORMATION

TIBSOVO may cause serious side effects, including:

  • Differentiation syndrome. Differentiation syndrome is a common condition that affects your blood cells and may be life-threatening or lead to death. Differentiation syndrome in adults with AML and MDS has happened as early as 1 day and up to 3 months after starting TIBSOVO. Call your healthcare provider or go to the nearest hospital emergency room right away if you develop any of the following symptoms of differentiation syndrome during treatment with TIBSOVO:

IMPORTANT SAFETY INFORMATION